Skip to main content
Erschienen in: CNS Drugs 8/2014

01.08.2014 | Original Research Article

Sociodemographic Disparities in Administration of Antiepileptic Drugs to Adults with Epilepsy in Germany: A Retrospective, Database Study of Drug Prescriptions

verfasst von: Hajo M. Hamer, Karel Kostev

Erschienen in: CNS Drugs | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Large epidemiological databases facilitate the study of medical care in different subgroups of the population and how such care compares with standard treatment guidelines. This study aimed for such analyses regarding utilization of antiepileptic drugs (AEDs) for epilepsy in Germany.

Method

The data source was the Disease Analyzer® database that is representative for the German population and assembles anonymous demographic and medical (diagnoses, prescriptions) data obtained from the practice computer system of general practitioners and specialists throughout Germany. A total of 43,712 adult patients with an epilepsy diagnosis (International Classification of Diseases, 10th edition [ICD10] code: G40.X) seen in 2010–2012 by 346 neurologists were retrospectively analysed according to sociodemographic characteristics, comorbidity, and AED treatment. Multivariate logistic regression was applied to calculate adjusted odds ratios (ORs) with 95 % confidence intervals (CIs).

Results

As compared with women, men were less likely to receive lamotrigine (OR 0.68; 95 % CI 0.65–0.72; p < 0.001) and were treated preferably with carbamazepine (OR 1.29; 95 % CI 1.23–1.35; p < 0.001). As compared with patients covered by private health insurance (PHI), patients with statutory health insurance (SHI) were treated more often with valproate (OR 1.19; 95 % CI 1.07–1.31; p < 0.001) and showed a higher rate of obesity (SHI: 3.1 %; PHI: 1.6 %; p < 0.001), while PHI was associated with administration of levetiracetam (OR 1.27; 95 % CI 1.16–1.4; p < 0.001). Carbamazepine (OR 1.25; 95 % CI 1.17–1.31; p < 0.001) and primidone (OR 1.23; 95 % CI 1.08–1.38; p < 0.001) were administered to a larger extent in rural versus urban areas. Lamotrigine (OR 1.31; 95 % CI 1.23–1.39; p < 0.001) was used more often in West than in East Germany. Living in an urban community raised the likelihood of being treated with levetiracetam (OR 1.23; 95 % CI 1.17–1.28; p < 0.001).

Conclusions

In spite of common guidelines, AED treatment differed significantly among adults with epilepsy in Germany. Besides gender, type of health insurance and place of residence strongly influenced AED administration.
Literatur
1.
Zurück zum Zitat Hamer HM, Dodel R, Strzelczyk A, Balzer-Geldsetzer M, Reese JP, Schoffski O, et al. Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany—a nationwide population-based study in children and adults. J Neurol. 2012;259(11):2376–84.PubMedCrossRef Hamer HM, Dodel R, Strzelczyk A, Balzer-Geldsetzer M, Reese JP, Schoffski O, et al. Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany—a nationwide population-based study in children and adults. J Neurol. 2012;259(11):2376–84.PubMedCrossRef
2.
Zurück zum Zitat Strzelczyk A, Haag A, Reese JP, Nickolay T, Oertel WH, Dodel R, et al. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany. Epilepsy Behav. 2013;27(3):433–8.PubMedCrossRef Strzelczyk A, Haag A, Reese JP, Nickolay T, Oertel WH, Dodel R, et al. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany. Epilepsy Behav. 2013;27(3):433–8.PubMedCrossRef
3.
Zurück zum Zitat Becher H, Kostev K, Schroder-Bernhardi D. Validity and representativeness of the “Disease Analyzer” patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther. 2009;47(10):617–26.PubMedCrossRef Becher H, Kostev K, Schroder-Bernhardi D. Validity and representativeness of the “Disease Analyzer” patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther. 2009;47(10):617–26.PubMedCrossRef
4.
Zurück zum Zitat Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1000–15.PubMedCentralPubMedCrossRef Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1000–15.PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Meyer AC, Dua T, Ma J, Saxena S, Birbeck G. Global disparities in the epilepsy treatment gap: a systematic review. Bul World Health Organ. 2010;88(4):260–6.CrossRef Meyer AC, Dua T, Ma J, Saxena S, Birbeck G. Global disparities in the epilepsy treatment gap: a systematic review. Bul World Health Organ. 2010;88(4):260–6.CrossRef
6.
Zurück zum Zitat Huber J, Mielck A. Morbidity and healthcare differences between insured in the statutory (“GKV”) and private health insurance (“PKV”) in Germany. Review of empirical studies. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010;53(9):925–38.PubMedCrossRef Huber J, Mielck A. Morbidity and healthcare differences between insured in the statutory (“GKV”) and private health insurance (“PKV”) in Germany. Review of empirical studies. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010;53(9):925–38.PubMedCrossRef
7.
Zurück zum Zitat Odeyemi IA, Nixon J. The role and uptake of private health insurance in different health care systems: are there lessons for developing countries? Clinicoecon Outcomes Res. 2013;5:109–18.PubMedCentralPubMedCrossRef Odeyemi IA, Nixon J. The role and uptake of private health insurance in different health care systems: are there lessons for developing countries? Clinicoecon Outcomes Res. 2013;5:109–18.PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Mattsson P, Tomson T, Eriksson O, Brannstrom L, Weitoft GR. Sociodemographic differences in antiepileptic drug prescriptions to adult epilepsy patients. Neurology. 2010;74(4):295–301.PubMedCrossRef Mattsson P, Tomson T, Eriksson O, Brannstrom L, Weitoft GR. Sociodemographic differences in antiepileptic drug prescriptions to adult epilepsy patients. Neurology. 2010;74(4):295–301.PubMedCrossRef
9.
Zurück zum Zitat Meyer AC, Dua T, Boscardin WJ, Escarce JJ, Saxena S, Birbeck GL. Critical determinants of the epilepsy treatment gap: a cross-national analysis in resource-limited settings. Epilepsia. 2012;53(12):2178–85.PubMedCrossRef Meyer AC, Dua T, Boscardin WJ, Escarce JJ, Saxena S, Birbeck GL. Critical determinants of the epilepsy treatment gap: a cross-national analysis in resource-limited settings. Epilepsia. 2012;53(12):2178–85.PubMedCrossRef
10.
Zurück zum Zitat Malmgren K, Flink R, Guekht AB, Michelucci R, Neville B, Pedersen B, et al. ILAE Commission of European Affairs Subcommission on European Guidelines 1998–2001: the provision of epilepsy care across Europe. Epilepsia. 2003;44(5):727–31.PubMedCrossRef Malmgren K, Flink R, Guekht AB, Michelucci R, Neville B, Pedersen B, et al. ILAE Commission of European Affairs Subcommission on European Guidelines 1998–2001: the provision of epilepsy care across Europe. Epilepsia. 2003;44(5):727–31.PubMedCrossRef
11.
Zurück zum Zitat Begley CE, Basu R, Reynolds T, Lairson DR, Dubinsky S, Newmark M, et al. Sociodemographic disparities in epilepsy care: results from the Houston/New York City health care use and outcomes study. Epilepsia. 2009;50(5):1040–50.PubMedCrossRef Begley CE, Basu R, Reynolds T, Lairson DR, Dubinsky S, Newmark M, et al. Sociodemographic disparities in epilepsy care: results from the Houston/New York City health care use and outcomes study. Epilepsia. 2009;50(5):1040–50.PubMedCrossRef
12.
Zurück zum Zitat Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, et al. Practice parameter update: management issues for women with epilepsy—focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009;73(2):133–41.PubMedCentralPubMedCrossRef Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, et al. Practice parameter update: management issues for women with epilepsy—focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009;73(2):133–41.PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Nunes VD, Sawyer L, Neilson J, Sarri G, Cross JH. Diagnosis and management of the epilepsies in adults and children: summary of updated NICE guidance. BMJ. 2012;344:e281.PubMedCrossRef Nunes VD, Sawyer L, Neilson J, Sarri G, Cross JH. Diagnosis and management of the epilepsies in adults and children: summary of updated NICE guidance. BMJ. 2012;344:e281.PubMedCrossRef
14.
Zurück zum Zitat Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011;10(7):609–17.PubMedCrossRef Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011;10(7):609–17.PubMedCrossRef
15.
Zurück zum Zitat Holden EW, Grossman E, Nguyen HT, Gunter MJ, Grebosky B, Von Worley A, et al. Developing a computer algorithm to identify epilepsy cases in managed care organizations. Dis Manag. 2005;8(1):1–14.PubMedCrossRef Holden EW, Grossman E, Nguyen HT, Gunter MJ, Grebosky B, Von Worley A, et al. Developing a computer algorithm to identify epilepsy cases in managed care organizations. Dis Manag. 2005;8(1):1–14.PubMedCrossRef
16.
Zurück zum Zitat Schnusenberg O, Loh CP, Nihalani K. The role of financial wellbeing, sociopolitical attitude, self-interest, and lifestyle in one’s attitude toward social health insurance. Appl Health Econ Health Policy. 2013;11(4):369–81.PubMedCrossRef Schnusenberg O, Loh CP, Nihalani K. The role of financial wellbeing, sociopolitical attitude, self-interest, and lifestyle in one’s attitude toward social health insurance. Appl Health Econ Health Policy. 2013;11(4):369–81.PubMedCrossRef
Metadaten
Titel
Sociodemographic Disparities in Administration of Antiepileptic Drugs to Adults with Epilepsy in Germany: A Retrospective, Database Study of Drug Prescriptions
verfasst von
Hajo M. Hamer
Karel Kostev
Publikationsdatum
01.08.2014
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 8/2014
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-014-0187-x

Weitere Artikel der Ausgabe 8/2014

CNS Drugs 8/2014 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.